Invivyd Inc. (IVVD) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, IVVD carries an RQD Score of 30 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The fundamental cash engine pillar scores 2 of 20, reflecting an ROIC of -35% and an FCF yield of 0%; for a prospective investor, this means the company is not currently generating returns on invested capital or free cash flow that would support the share price on earnings alone. The whale/13F flow pillar scores 12 of 20, indicating institutional accumulation and options positioning that partially offset the weak fundamentals, though the source data does not itemize specific holder positions. The insider conviction pillar scores 3 of 20, based on the SEC Form 4 and Congressional PTR cluster flow referenced in the rating; the news wire also notes insider purchases of a small dollar amount, which the rating treats as weak conviction. The macro regime fit pillar scores 8 of 20, with a beta of 1.0 and sector sensitivity noted. The forensic balance sheet pillar scores 5 of 20, reflecting an Altman Z-Score of 0.2, a Piotroski F-Score of 3/9, and a Debt/Equity ratio of 0.5. Taken together, the rating frames IVVD as a high-forensic-risk name where upside would depend on a catalyst (such as regulatory progress) rather than on current cash generation, and where valuation tradeoffs are dominated by the gap between a $177.4M market cap and negative operating economics.

Per the SEC financials, reported operating margin and net margin are both -60%, and gross margin is 0%. ROIC is -35% per the market data. The Altman Z-Score is 0.2 and the Piotroski F-Score is 3/9, per the Roarable RQD rating forensic balance sheet pillar, with a Debt/Equity ratio of 0.5. Reported cash rose to $226.7M in FY 2025 from $69.3M in FY 2024, while FCF remained negative in each reported period.

Per the recent news and catalysts feed, the headlines include: an inducement grants disclosure under Nasdaq Listing Rule 5635(c)(4); a TradingView estimates page; a Moomoo options chain page; a Stock Titan report on options to buy 157,500 shares granted to six new hires; a Simply Wall St report noting insider purchases losing another US$89k; and a Yahoo Finance report that VYD2311 Phase III met safety goals and the company is eyeing FDA accelerated approval. Each item is flagged YELLOW with impact label MARKET WIRE. The VYD2311 Phase III safety readout is the most material catalyst referenced, while the insider-purchase item is a negative price-action signal. Per the Butterfly Supply-Chain Graph, no proprietary signals or supply-chain links are provided.

• What is the company's specific product portfolio and revenue composition behind the FY 2025 revenue of $53.4M?
• What are the terms and timing of the FDA accelerated approval path referenced for VYD2311?
• What are the debt terms, since the debt field is N/A across all reported periods?
• What is the cash runway implied by the $226.7M cash balance against negative FCF?
• What are the specific 13F holder positions and Form 4 transaction details behind the RQD whale and insider pillars?